Abstract
To obtain a three-month release injection of leuprorelin acetate, microspheres were prepared with copoly(DL-lactic/glycolic acid) or poly(DL-lactic acid) (PLA) using an in-water drying method, and drug release was evaluated. The content of water-soluble oligomers in the polymers was found to strongly affect the initial burst, and reducing the content to less than 0.1% was necessary to keep the first-day release below 10%. Drug loading of more than 15% also increased the initial drug release; the acceptable maximum loading was 12%. Elevation of the glass transition temperature of the microspheres was observed with an increase in drug loading. This suggests formation of a rigid structure, possibly with arrangement of the polymer around the drug cores like in a micelle. This structure provides a hydrophobic barrier against diffusion of the hydrophilic peptide, resulting in high trapping efficiency and long-term sustained release dependent on polymer erosion. The microspheres prepared with PLA having a m.w. of 12,000 to 18,000 provided linear sustained release and persistent serum levels of the drug in rats for over 3 months.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
H. Okada, Y. Inoue, Y. Ogawa, and H. Toguchi. Three-month release injectable microspheres of leuprorelin acetate. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 19:52–53 (1992).
H. Okada, T. Heya, Y. Inoue, M. Yamamoto, Y. Ogawa, and H. Toguchi. Sustained release injection of therapeutic peptides for long periods. Polymer Preprints, Japan 41:E1237 (1992).
H. Okada, Y. Ogawa, and T. Yashiki. Prolonged release microcapsules and their production. U. S. Patent 4652441 (1987).
Y. Ogawa, M. Yamamoto, H. Okada, T. Yashiki, and T. Shimamoto. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly (lactic/glycolic) acid. Chem. Pharm. Bull. 36:1095–1103 (1988).
H. Okada, T. Heya, Y. Ogawa, and T. Shimamoto. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. J. Pharmacol. Exp. Ther. 244:744–750 (1988).
H. Okada. One-month release injectable microspheres of leuprolide acetate, a superactive agonist of LH-RH. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 16:12–13 (1989).
H. Okada, T. Heya, Y. Igari, Y. Ogawa, H. Toguchi, and T. Shimamoto. One-month release injectable microspheres of leuprolide acetate inhibit steroidogenesis and genital organ growth in rats. Int. J. Pharm. 54:231–239 (1989).
Y. Ogawa, H. Okada, T. Heya, and T. Shimamoto. Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: Serum drug level profiles and pharmacological effects in animals. J. Pharm. Pharmacol. 41:439–444 (1989).
H. Okada, T. Heya, Y. Ogawa, H. Toguchi, and T. Shimamoto. Sustained pharmacological activities in rats following single and repeated administration of once-a-month injectable microspheres of leuprolide acetate. Pharm. Res. 8:584–587 (1991).
H. Okada, Y. Inoue, T. Heya, H. Ueno, Y. Ogawa, and H. Toguchi. Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate. Pharm. Res. 8:787–791 (1991).
R. Sharifi, M. Soloway, and the Leuprolide Study Group. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J. Urol. 143:68–71 (1990).
A. J. Friedman, B. Benacerraf, D. Harrison-Atlas, R. Gleason, R. L. Barbieri, and I. Schiff. A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomate. Fertil. Steril. 51:251–256 (1989).
A. M. Dlugi, J. D. Miller, J. Knittle, and the Lupron Study Group. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Fertil. Steril. 54:419–427 (1990).
J. H. R. Woodland and S. Yelles. Long-acting delivery systems for narcotic antagonists. 1. J. Med. Chem. 16:897–901 (1973).
Y. Ogawa, H. Okada, M. Yamamoto, and T. Shimamoto. In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lactic/glycolic) acids and in vivo degradation of these polymers. Chem. Pharm. Bull. 36:2576–2581 (1988).
F. D. Anderson, D. F. Archer, S. M. Harman, R-J. Leonard, and W. H. Wilborn. Tissue response to biorodible, subcutaneous drug implants: A possible determinant of drug absorption kinetics. Pharm. Res. 10:369–380 (1993).
K. Makino, M. Arakawa, and T. Kondo. Preparation and in vitro degradation properties of polylactide microcapsules. Chem. Pharm. Bull. 33:1195–1201 (1985).
G. E. Visscher, R. L. Robinson, and G. J. Argentieri. Tissue response to biodegradable injectable microcapsules. J. Biomater. Appl. 2:118–131 (1987).
T. Heya, H. Okada, Y. Tanigawara, Y. Ogawa, and H. Toguchi. Effects of counteranion of TRH and loading amount on control of TRH release from copoly(dl-lactic/glycolic acid) microspheres prepared by an in-water drying method. Int. J. Pharm. 69:69–75 (1991).
A. Sanchez, J. L. Vila-Jato, and M. J. Alonso. Development of biodegradable microspheres and nanospheres for the controlled release of cyclosporin A. Int. J. Pharm. 99:263–273 (1993).
H. Okada, M. Yamamoto, T. Heya, Y. Inoue, S. Kamei, Y. Ogawa, and H. Toguchi. Drug delivery using biodegradable microspheres. J. Cont. Rel. 28:121–129 (1994).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Okada, H., Doken, Y., Ogawa, Y. et al. Preparation of Three-Month Depot Injectable Microspheres of Leuprorelin Acetate Using Biodegradable Polymers. Pharm Res 11, 1143–1147 (1994). https://doi.org/10.1023/A:1018936815654
Issue Date:
DOI: https://doi.org/10.1023/A:1018936815654